0001209191-18-054150.txt : 20181003
0001209191-18-054150.hdr.sgml : 20181003
20181003200025
ACCESSION NUMBER: 0001209191-18-054150
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20181001
FILED AS OF DATE: 20181003
DATE AS OF CHANGE: 20181003
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: SLATTERY JOSEPH P
CENTRAL INDEX KEY: 0001246530
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-19437
FILM NUMBER: 181106687
MAIL ADDRESS:
STREET 1: C/O TRANSENTERIX, INC.
STREET 2: 635 DAVIS DRIVE, SUITE 300
CITY: MORRISVILLE
STATE: NC
ZIP: 27560
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: TRANSENTERIX INC.
CENTRAL INDEX KEY: 0000876378
STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
IRS NUMBER: 112962080
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 635 DAVIS DRIVE
STREET 2: SUITE 300
CITY: MORRISVILLE
STATE: NC
ZIP: 27560
BUSINESS PHONE: 919-765-8400
MAIL ADDRESS:
STREET 1: 635 DAVIS DRIVE
STREET 2: SUITE 300
CITY: MORRISVILLE
STATE: NC
ZIP: 27560
FORMER COMPANY:
FORMER CONFORMED NAME: SafeStitch Medical, Inc.
DATE OF NAME CHANGE: 20080211
FORMER COMPANY:
FORMER CONFORMED NAME: CELLULAR TECHNICAL SERVICES CO INC
DATE OF NAME CHANGE: 19930328
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2018-10-01
0
0000876378
TRANSENTERIX INC.
TRXC
0001246530
SLATTERY JOSEPH P
C/O TRANSENTERIX, INC.
635 DAVIS DRIVE, SUITE 300
MORRISVILLE
NC
27560
0
1
0
0
EVP and CFO
Common Stock
2018-10-01
4
M
0
11951
1.42
A
11951
D
Common Stock
2018-10-01
4
M
0
9375
1.53
A
21326
D
Common Stock
2018-10-01
4
M
0
6250
2.45
A
27576
D
Common Stock
2018-10-01
4
M
0
11250
2.94
A
38826
D
Common Stock
2018-10-01
4
M
0
13750
3.82
A
52576
D
Common Stock
2018-10-01
4
M
0
3575
4.02
A
56151
D
Common Stock
2018-10-01
4
S
0
56151
5.73
D
0
D
Common Stock
2018-10-02
4
M
0
8500
1.42
A
8500
D
Common Stock
2018-10-02
4
S
0
8500
5.77
D
0
D
Common Stock
25000
I
By IRA
Stock Option
1.42
2018-10-01
4
M
0
11951
0.00
D
2027-02-02
Common Stock
11951
245334
D
Stock Option
1.53
2018-10-01
4
M
0
9375
0.00
D
2026-10-25
Common Stock
9375
78125
D
Stock Option
2.45
2018-10-01
4
M
0
6250
0.00
D
2025-10-28
Common Stock
6250
27084
D
Stock Option
2.94
2018-10-01
4
M
0
11250
0.00
D
2025-02-04
Common Stock
11250
28126
D
Stock Option
3.82
2018-10-01
4
M
0
13750
0.00
D
2026-02-12
Common Stock
13750
116875
D
Stock Option
4.02
2018-10-01
4
M
0
3575
0.00
D
2024-04-21
Common Stock
3575
461426
D
Stock Option
1.42
2018-10-02
4
M
0
8500
0.00
D
2027-02-02
Common Stock
8500
236834
D
The transaction occurred pursuant to a written trading plan dated November 29, 2017 meeting the requirements of Rule 10b5-1(c).
The sale price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.64 to $5.805 inclusive. The reporting person undertakes to provide to TransEnterix, Inc., any security holder of TransEnterix, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.
The sale price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.75 to $5.78. inclusive. The reporting person undertakes to provide to TransEnterix, Inc., any security holder of TransEnterix, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.
Following the sales on October 1, 2018, the reporting person continues to beneficially own 25,000 shares of the company's common stock. The reporting person also holds stock options to acquire 1,749,470 shares of common stock, of which approximately 26% are vested, and restricted stock units representing an additional 595,777 shares of common stock subject to forfeiture restrictions.
Vests 25% on the first anniversary of the date of grant and 1/48th of the entire award monthly on the vesting date anniversary for 36 months, subject to acceleration as set forth in the Incentive Plan and the reporting person's Employment Agreement with the Company.
Fully vested.
/s/ Joshua Weingard, as Attorney-in-Fact for Joseph Slattery
2018-10-03